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Abstract 
 
Polypharmacy has been linked to higher risks of hospitalisation and death in community 
samples. It is commonly present in people with dementia but these risks have rarely been 
studied in this population. We aimed investigate associations between polypharmacy and 
emergency department attendance, any and unplanned hospitalisation, and mortality in 
patients with dementia. Using a large mental health care database in South London, linked to 
hospitalisation and mortality data, we assembled a retrospective cohort of patients diagnosed 
with dementia. We ascertained number of medications prescribed at the time of dementia 
diagnosis and conducted a multivariate Cox regression analyses. Of 4,668 patients with 
dementia identified, 1,128 (24.2%) were prescribed 4-6 medications and 739 (15.8%) ≥7 
medications. Compared to those using 0-3 medications, patients with dementia using 4-6 or 
≥7 agents had an increased risk of emergency department attendance (hazard ratio 1.20 / 
1.35), hospitalisation (hazard ratio 1.12 / 1.32), unplanned hospital admission (hazard ratio 
1.12 / 1.25), and death within two years (hazard ratio 1.29 /1.39) after controlling for potential 
confounders. We found evidence of a dose response relationship with each additional drug at 
baseline increasing the risk of emergency department attendance and mortality by 5% and 
hospitalisation by 3%. In conclusion, polypharmacy at dementia diagnosis is associated with 
a higher risk of adverse health outcomes. Future research is required to elucidate which 
specific agents underlie this relationship and if reduction of inappropriate prescribing is 
effective in preventing adverse health outcomes in dementia. 
 
Keywords: dementia; hospitalisation; mortality; emergency department; polypharmacy; 
pharmacoepidemiology  
 
 
Highlights: 
• Polypharmacy in patients with dementia is associated with an increased risk of 
emergency department attendance, hospitalisation, unplanned hospital admission and 
death.  
• Risk of emergency department attendance is increased by 20% in those taking 4-6 
medications and by 35% in patients taking ≥7 medications. 
• Hospitalisation risk is increased by 12% in those taking 4-6 medications and by 32% 
in patients taking ≥7 medications. 
• A dose-response relationship exists between the number of medications at dementia 
diagnosis and adverse health outcomes.  
  
 1. Introduction 
 
Compared to the general older population, people with dementia have high rates of physical 
and psychiatric co-morbidity, often resulting in the prescription of multiple medications 
simultaneously (Andersen and others 2011; Clague and others 2016). Clinical practice 
guidelines and policies tend to provide advice for single conditions, such as dementia or 
cardiovascular disease, and their applicability to patients with multiple co-morbidities is often 
unclear. Individual medications, which are beneficial and well-evaluated in a single condition, 
may lose their effect or even be harmful when taken in combination with other medications, 
due to drug-drug interactions, and little evidence exists on the efficacy, safety and tolerability 
of medications used to manage co-morbidities in dementia (Duerden M 2013; Reeve and 
others 2015). People with dementia are often excluded from clinical trials, from which 
guideline-based treatments for long-term conditions commonly arise (Brauner and others 
2000; Parsons 2017). Further, typical dementia symptoms, such as declining memory, 
executive function, language and agitation might prevent adverse drug events from being 
detected early and before they lead to more serious complications and subsequent 
hospitalisation (Onder and others 2011).  
 
In community samples of older people, polypharmacy has been linked to inappropriate 
prescribing (Guthrie and others 2011), adverse drug events (Bourgeois and others 2010), 
preventable and unplanned hospitalisation (Leendertse and others 2008; Payne and others 
2014), increased mortality (Gnjidic and others 2012; Richardson and others 2011), reduced 
adherence (Vik and others 2004), higher risk of falls (Richardson and others 2015) and frailty 
(Veronese and others 2017), and impaired quality of life (Fincke and others 1998). However, 
despite the reported high levels of polypharmacy in people with dementia very little is known 
about potential adverse health outcomes in this group (Parsons 2017), apart from one study 
of nursing home residents with severe dementia, in whom the prescription of 10 or more 
medications was associated with a higher mortality risk (Onder and others 2013).    
We sought to investigate if polypharmacy is associated with four important outcomes – 
emergency department attendance, any and unplanned hospital admissions, and mortality – 
in a large, naturalistic sample of people with dementia.  
 
  
2. Methods 
 
2.1 Data source: 
Data were obtained from the South London and Maudsley NHS Foundation Trust (SLaM) 
Clinical Record Interactive Search (CRIS) application. SLaM is one of Europe’s largest 
healthcare providers for dementia and other mental disorders, serving a population of over 1.2 
million residents, and has adopted fully-electronic health records for all services since 2006. 
CRIS provides research access to more than 270,000 de-identified health records from SLaM 
within a robust governance framework (Perera and others 2016; Stewart and others 2009), 
and has received ethical approval as an anonymized data resource (Oxford Research Ethics 
Committee C, reference 08/H0606/71+5).  
Data of interest were extracted either from structured fields or from clinical documents through 
bespoke natural language processing algorithms using General Architecture for Text 
Engineering (GATE) software (Cunningham 2002; Perera and others 2016). Further, CRIS 
has been linked to national data on hospitalisation (Hospital Episode Statistics; HES) and 
mortality, enabling relevant health outcome data to be extracted for the current analyses. 
 
2.2 Sample: 
CRIS was used to extract cases aged 65 years or older who received a first dementia 
diagnosis from SLaM outpatient services within the period between 1st Jan 2006 and 31st 
March 2011. This a allowed a two year follow-up period as hopitalisation (HES)  data were 
avalible until 31st March 2013.  
 
2.3 Polypharmacy (exposure): 
Number of medications recorded in text fields (case notes, clinical correspondence) in a 6-
month window around the dementia diagnosis was ascertained using a GATE-supported 
natural language processing algorithm previously described (Perera and others 2016). This 
serves as a measure for prevalent polypharmacy as patients’ medication might not be 
recorded in electronic health records at the same time as the diagnosis. There is no single 
agreed definition of polypharmacy (Guthrie and others 2011); hence we used the 
categorization suggested in the development of multidimensional prognostic index, applying 
three groups: 0-3 (reference group), 4-6 or >7 medications (Pilotto and others 2008). This 
scale has been applied in similar analyses, which also have been able to demonstrate dose-
response relationships (Veronese and others 2017). 
 
2.4 Outcomes: 
From linked national data we ascertained any and unplanned hospitalisations for physical 
disorders, emergency department attendances and mortality in the two years after dementia 
diagnosis using Hospital Episode Statistics (HES; NHS Digital). The HES database records 
all admissions to all National Health Service (NHS) hospitals in England, and includes 
diagnoses and procedures. Within the NHS, HES allows tracking of patients between different 
hospitals and across different years. To determine the causes of hospitalisation and death we 
extracted the ten most common primary discharge diagnoses and causes of death according 
to ICD-10 codes (World Health Organisation 2010) from HES and Office of National Statistics 
records.   
 
2.5 Covariates: 
We extracted data on a range of potential confounders which we ascertained at the time of 
dementia diagnosis (baseline). These comprised socio-demographic factors (age, gender, 
marital status, ethnicity, and a neighbourhood-level index of multiple deprivation (Noble and 
others 2007)), level of cognitive impairment as measured by Mini-Mental State Examination 
(MMSE) (Folstein and others 1975) score closest to the diagnosis and two measures of 
general physical health and co-morbidity: i) hospitalisation in the two years prior to dementia 
diagnosis, and ii) the ‘Problems related to physical illness or disability’ subscale of the Health 
of the Nation Outcome Scales (HoNOS65+) instrument. The HoNOS65+ is a standard 
measure of patient wellbeing used in UK (Burns and others 1999) mental health and dementia 
services whose performance has been previously reported (Pirkis and others 2005) and 
subscales are each rated 0 (no problem) to 4 (severe or very severe problem). To determine 
the burden of co-morbid neuropsychiatric symptoms, we established the number of mental 
health subscales in HoNOS65+ (behavioural disturbance, non-accidental self-injury, 
substance use, hallucinations and/or delusions, depressive symptoms) in which the patient 
was scored to have at least a mild problem (score of 2 to 4). From structured fields and free-
text documents we ascertained the dementia subtype diagnosis (Alzheimer’s disease, 
vascular dementia, mixed-type dementia, Lewy body dementias, unspecified dementia).  
 
2.6 Statistical analysis 
Analyses were conducted using STATA 13 software (Stata Corp LP, College Station, TX, 
USA). Differences in the study population across the three levels of prescribing (0-3, 4-6, 7+ 
medications) were examined using linear regression models for continuous and logistic 
regression models for binary variables. Multivariable Cox regression models were used to 
calculate associations between polypharmacy and the aforementioned outcomes, with 
patients receiving 0-3 medications defined as the reference group. Censoring point was either 
the date of emergency department attendance/hospitalisation, date of death or the two-year 
mark after dementia diagnosis. Results are reported as hazard ratios (HR) with 95% 
confidence intervals (CIs). Analyses were initially adjusted for age, gender and MMSE score, 
and then for age, gender, ethnicity, marital status, MMSE score, deprivation score, HoNOS65+ 
‘Problems related to physical illness or disability’ subscale (all at time of dementia diagnosis), 
hospitalisation in the two years prior to dementia diagnosis and any recorded vascular 
dementia diagnosis. As medications prescribed specifically for dementia (Lau and others 
2010) contribute to the burden of polypharmacy and might pose their own hazards in this 
population, we carried out sensitivity analyses accounting for prescription of antipsychotics, 
antidepressants, hypnotics, or anticholinergic medications within six months before or after 
the dementia diagnosis date.  
 
3. Results 
 
We identified 6,253 patients diagnosed with dementia in SLaM outpatient services within the 
observation period. After excluding 413 (6.6%) patients who were under the age of 65 at the 
time of dementia diagnosis, 909 (14.5%) without recorded MMSE score and 262 (4.2%) 
lacking information on physical health, the sample consisted of 4,668 patients.  
 
Of these, 64.2% were female and 18.2% from a minority ethnic group. Mean age at dementia 
diagnosis was 81.7 (SD ±6.9) years. Mean MMSE score was in the mild to moderate dementia 
range (18.4 ± 6.3). In the entire sample, median number of medications prescribed was 3 
(range: 0-24).  
 
Patient characteristics according to medication use are presented in Table 1. Participants 
using 7 or more medications were younger, more likely to be male and from a minority ethnic 
group; moreover, they resided in more deprived neighbourhoods, had more neuropsychiatric 
problems and worse physical health, mirrored in a higher physical illness HoNOS65+ score 
and a higher likelihood of hospitalisation in the previous two years. Diagnoses of vascular or 
mixed-type dementia, as well as Lewy body dementias, were associated with higher levels of 
polypharmacy. 
 
Across the entire sample, 2,828 (60.6%) participants attended an emergency department in 
the follow-up period of two years after dementia diagnosis, 3,105 (66.5%) had at least one 
hospitalisation, 2,718 (58.2%) at least one unplanned admission and 1,142 (24.5%) died. 
Associations between medication use and these outcomes are presented in Table 2. Taking 
those using up to three medications as a reference group, patients prescribed 4-6 and ≥7 
agents showed progressively increased risks of hospitalisation, emergency department 
attendance and mortality over the two-year follow-up. The age-, gender- and MMSE-adjusted 
hazard ratios lay between 1.21 to 1.37 for patients prescribed 4-6 medications and between 
1.54 to 1.63 for patients prescribed 7 or more medications for these negative health outcomes, 
and remained statistically significant and relatively strong after adjustment for a broad range 
of potential confounders including physical illness severity scores and hospitalisations prior to 
the dementia diagnosis. Figure 1 shows Kaplan-Meier curves comparing time to first 
hospitalisation between the exposure groups. On further analysis applying the count of 
medications as an ordinal variable, each additional drug at baseline increased the risk of 
emergency department attendance and death within two years (each by 5%) and any and 
unplanned hospitalisation (by 3%). Sensitivity analyses accounting for potentially hazardous 
medications (see Supplementary Table 1) as co-variates, did not affect risks for the four 
outcomes substantially. Compared to those taking 0-3 medications, patients taking 4-6 
medications were more frequently admitted due to pneumonia and other lower respiratory 
tract infections and this was also significantly more often recorded as cause of death in this 
group (p=0.034). Patients taking 7 or more medications were more frequently admitted due to 
ischaemic heart disease. Frequency of other common causes of hospitalisation, including hip 
fractures and head injuries, and mortality didn’t differ between groups (see Supplementary 
Tables 1 & 2).  
 
Table 1: Characteristics of patients with dementia classified according to medication usage 
 
 0-3 medications 
(n=2,801; 60.0%) 
4-6 medications 
(n=1,128; 24.2%) 
≥7 medications 
(n=739; 15.8%) 
P1 (4-6 vs 0-3) P1 (≥7 vs 0-3) 
Socio-demographics2      
Age (years, mean, SD) 81.8 (6.9) 82.0 (6.8) 81.2 (6.7) 0.347 0.034 
Female (%) 64.8% 64.8% 60.8% 0.985 0.040 
Non-White Ethnicity (%) 17.6% 17.9% 21.0% 0.500 <0.001 
Married or cohabiting (%) 34.9% 36.9% 32.4% 0.580 0.220 
Deprivation score (mean, SD) 26.4 (11.3) 26.9 (11.2) 28.7 (10.4) 0.178 <0.001 
MMSE score (mean, SD) 18.7 (6.3) 18.1 (6.3) 18.1 (6.5) 0.008 0.020 
Physical illness or disability3      
0-1 (no or minor problem) 57.9% 47.9% 35.3% <0.001 <0.001 
2 (mild problem) 21.5% 25.8% 31.8% 0.004 <0.001 
3-4  (moderately severe to very severe problem) 20.6% 26.3% 32.9% <0.001 <0.001 
      
Co-morbid non-cognitive mental health problems4      
No additional mental health problems 70.8% 59.4% 44.2% <0.001 <0.001 
One additional mental health problems 21.6% 28.8% 35.3% <0.001 <0.001 
Two or more additional mental health problems 7.6% 11.8% 20.5% <0.001 <0.001 
      
Hospitalisation5      
Any (planned and unplanned) hospitalisation  51.5% 58.5% 72.5% <0.001 <0.001 
Unplanned hospitalisation  39.3% 48.2% 65.0% <0.001 <0.001 
 
Dementia subtype 
     
Alzheimer’s disease   44.2% 36.0% 24.6% <0.001 <0.001 
Vascular dementia   17.9% 25.4% 30.0% <0.001 <0.001 
Mixed-type dementia (including Alzheimer’s disease and Vascular dementia) 22.5% 25.4% 29.% 0.052 <0.001 
Lewy body dementias (Dementia with Lewy bodies or Parkinson’s disease dementia) 2.1% 4.2% 7.0% <0.001 <0.001 
Unspecified dementia 11.7% 7.5% 6.1% <0.001 <0.001 
 
1 using linear regression for continuous and logistic regression for ordinal variables 
2 at the time of dementia diagnosis 
3 ascertained via HoNOS65+ ‘Problems related to physical illness or disability’ subscale 
4 Number of HoNOS65+ subscales with score of 2 or more (behavioural disturbance, non-accidental self-injury, substance use, hallucinations 
and/or delusions, depressive symptoms) 
5 hospitalisations in the 2 years prior to dementia diagnosis from Hospital Episode Statistics 
 
 
  
Table 2: Adjusted hazard ratios for categories of medication use and outcomes using multivariable cox regression in 
patients with dementia 
 
 Emergency department attendance Hospitalisation Unplanned hospitalisation Mortality 
 Cumulative 
incidence 
(%) 
Age & 
gender, 
MMSE 
adjusted 
HR (95% 
CI) 
Fully 
adjusted 
HR±  (95% 
CI) 
Cumulative 
incidence 
(%) 
Age & 
gender, 
MMSE 
adjusted 
HR (95% 
CI) 
Fully 
adjusted 
HR±  (95% 
CI) 
Cumulative 
incidence 
(%) 
Age & 
gender, 
MMSE 
adjusted 
HR (95% 
CI) 
Fully 
adjusted 
HR±  (95% 
CI) 
Cumulative 
incidence 
(%) 
Age & 
gender 
adjusted 
HR (95% 
CI) 
Fully 
adjusted 
HR±  (95% 
CI) 
0-3 
medications 
57.1% 1 
[reference] 
1 
[reference] 
63.0% 1 
[reference] 
1 
[reference] 
54.6% 1 
[reference] 
1 
[reference] 
21.2% 1 
[reference] 
1 
[reference] 
4-6 
medications 
64.6% 1.27 (1.16-
1.39)* 
1.20 (1.09-
1.31)* 
69.2% 1.21 (1.11-
1.32)* 
1.12 (1.02-
1.22)# 
61.4% 1.21 (1.11-
1.33)* 
1.12 (1.02-
1.23)# 
28.2% 1.37 (1.20-
1.57)* 
1.29 (1.11-
1.49)* 
> 7 
medications 
67.5% 1.54 (1.39-
1.71)* 
1.35 (1.21-
1.51)* 
75.9% 1.63 (1.48-
1.79)* 
1.32 (1.19-
1.47)* 
67.1% 1.56 (1.41-
1.72)* 
1.25 (1.11-
1.40)* 
31.1% 1.61 (1.38-
1.87)* 
1.39 (1.17-
1.66) 
Risk 
increase per 
additional 
medication  
 1.06 (1.05-
1.07)* 
1.05 (1.03-
1.06)* 
 1.06 (1.04-
1.07)* 
1.03 (1.02-
1.04)* 
 1.05 (1.04-
1.07)* 
1.03 (1.02-
1.04)* 
 1.06 (1.05-
1.08)* 
1.05 (1.03-
1.07)* 
 
* p<0.01 
# p<0.05  
 
±Fully adjusted model included as covariates: age, gender, ethnicity, marital status, MMSE score, deprivation score, HoNOS65+ physical illness 
problem score, number of co-morbid non-cognitive mental health problems (all at time of dementia diagnosis); if hospitalised in two years prior 
to dementia diagnosis; dementia subtype 
 
  
Figure 1: Kaplan-Meier curves displaying time to first hospitalisation after dementia diagnosis by number of medications prescribed 
 
4. Discussion 
 
In this study of more than 4,000 patients diagnosed in a specialist dementia care and 
assessment provider we demonstrated that polypharmacy is associated with an increased risk 
of emergency department attendance, and both any and unplanned hospitalisation, as well as 
mortality over a two-year follow-up period. We further demonstrated a dose-response 
relationship between number of medications prescribed and negative outcomes in all four 
outcomes.  
 
Hospitalisation is a common and unwanted event for people with dementia (Rao and others 
2016) and may increase the risk of delirium, functional decline and death itself (Mathews and 
others 2014). Thus, understanding potentially modifiable factors for hospitalisation is 
essential. However, little is known about polypharmacy and hospitalisation in dementia (Russ 
and others 2015). To our knowledge, previous studies have been almost entirely restricted to 
community samples of unselected older populations. In an elderly all male community-dwelling 
population, Beer and colleagues (Beer and others 2011) found a 4% increased risk of 
hospitalisation per additional medication prescribed. In a smaller study, with less rigorous 
adjustment for chronic illness, Jensen and colleagues (Jensen and others 2001) found 3.8 
times increased odds for hospitalisation in older community-dwelling Medicare beneficiaries 
using three or more medications. In residential settings, an Italian study (Cherubini and others 
2012) of 1,466 nursing home residents, of whom 70% suffered from cognitive impairment, 
reported that polypharmacy (defined as the concurrent use of 5 or more medications) was 
associated with hospitalisation in a mixed-effects logistic regression model adjusted for co-
morbidity (effect size: 0.54; p<0.01). Similarly, an Australian long-term care study (Lalic and 
others 2016) demonstrated an increased risk of hospitalisation in relation to being prescribed 
9 or more medications (hazard ratio 1.84; p<0.01). Thus, our data expand the previous 
literature to dementia populations and confirms that the higher hospitalisation risk described 
in general older populations is also applicable in people with dementia. Further, our study 
shows that polypharmacy is associated with an increased risk of emergency department 
attendance, which is inherently related to hospitalisation.  
 
Mortality is the only outcome which has been previously evaluated in dementia in relation to 
polypharmacy. The SHELTER care home study found that excessive polypharmacy, defined 
as being prescribed 10 or more medications, was associated with at 119% increased risk of 
death in those with limited life expectancy (Onder and others 2013).  Although important, the 
SHELTER study (Onder and others 2013) has some limitations, such as only including 
participants from nursing homes and including a relatively small sample size (only 822 
residents). Studies on polypharmacy-related mortality in community-dwelling older adults 
have only been carried out in unselected general populations. Two studies (Beer and others 
2011; Gnjidic and others 2012), which had good adjustment for chronic illness (Fried and 
others 2014), found the risk of death increased by 4% - 9% for each additional medication 
prescribed. Defining polypharmacy as the concomitant prescription of 5 or more medications, 
Richardson and colleagues (Richardson and others 2011) found a 42% increased risk of two-
year mortality for men and 30% for women. Although we cannot distinguish between 
community-dwelling and institutionalised participants, our study is the first to examine mortality 
in relation to polypharmacy in a wider group of dementia patients from both settings and better 
representativeness of the source population. 
 
Several factors could explain why polypharmacy is linked to higher risk of adverse health 
outcomes in dementia populations. Possible mediators of this interaction are adverse drug 
events which are associated with polypharmacy (Bourgeois and others 2010), preventable 
medication related hospitalisation in older people (Leendertse and others 2008) and mortality 
(Pardo Cabello and others 2016).  Further, the link between polypharmacy and inappropriate 
prescribing is well established (Guthrie and others 2011), which has in turn been implicated in 
higher hospitalisation risk (Hamilton and others 2011). Specifically, in dementia antipsychotics 
and antidepressants have been associated with increased risk of mortality (Corbett and others 
2014; Mueller and others 2017). In our study, risk of hospitalisation and mortality remained 
significantly related to polypharmacy after accounting for potentially hazardous medications 
(see Supplementary Table 1), indicating that other potentially inappropriate medications or 
polypharmacy itself remain independent risk factors. Few significant differences were detected 
in reasons for hospitalisation and mortality in this study, indicating that polypharmacy might 
exert its primary effect by hastening the occurrence of these outcomes.  
 
Strengths of the current study include the broad range of data available for our large sample.  
This allowed adjustment for a number of confounders, including cognitive and deprivation 
scores, a physical illness problem score and previous hospitalisation as a measure of multi-
morbidity, vascular disease, psychotropic and anticholinergic medication.  
 
Our study has a number of limitations. First, while data from a specialist dementia assessment 
and care provider ensures an expert diagnosis, we cannot rule out under-recording of physical 
health medications. This would however imply that patients in our 0-3 medications references 
group are potentially taking more medication and we are underestimating the hazards of 
polypharmacy. Second, the software ascertained prescribed medication in a 6-month window 
around dementia diagnosis, which means that that medications prescribed as a consequence 
of the dementia diagnosis or an early hospitalisation would be captured. Nevertheless, those 
dementia-specific medications do also contribute to the polypharmacy burden. Third, multi-
morbidity was captured through recoding of hospitalisation prior to dementia diagnosis and 
the HoNOS65+ physical illness subscale. Despite being a widely used routine measure of 
clinical outcome in mental health and dementia services in the UK (Pirkis and others 2005), 
the scale is relatively brief without details on the specific long-term conditions determining its 
score. Finally, in observational studies there always remains the possibility of residual 
unmeasured confounders which may affect outcomes, although we have adjusted for wide 
range of social, pharmacoepidemiological and mental and physical health factors.   
 
4.1 Conclusions 
Polypharmacy at the time of dementia diagnosis is associated with an at least 20% 
increased risk of emergency department attendance, at least 12% increased risk of any or 
unplanned hospitalisation and least 29% increased risk of early mortality. Given that almost 
50 million people have dementia world-wide, with an expected increase of close to 10 million 
cases every year (Prince and others 2013), and growing levels of polypharmacy reported 
(Qato and others 2016), these relatively small, but consistent, increased risks may have 
considerable  public health and healthcare delivery consequences.  Future analyses could 
explore this association in more detail using inappropriate prescribing criteria (e.g. Beers (By 
the American Geriatrics Society Beers Criteria Update Expert 2015) or STOPP (O'Mahony 
and others 2015) criteria) or assess the wanted and unwanted effects of medications on 
certain receptor groups (e.g. using the Anticholinergic Effect on Cognition (AEC) scale 
(Bishara and others 2017)).  The ‘Medication Appropriateness Tool for Comorbid Health 
conditions during Dementia’ (MATCH-D) developed by Page and colleagues using the 
Delphi technique [12] advocates  an individualised treatment approach, giving guidance on 
treatment goals and use of preventative medications according to dementia severity stage, 
as well as on symptomatic, psychotropic and antidementia medications. If such a tool 
enables reduction of polypharmacy, the related hazards described in this analysis, and 
ultimately improves outcomes, requires further evaluation.  
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